Breast Cancer Update, Issue 3, 2018
Interview with Joyce O’Shaughnessy, MD
Interview with Erica L Mayer, MD, MPH
Track 1:
Preliminary results from the Phase III KATHERINE study evaluating T-DM1 versus trastuzumab as adjuvant therapy for patients with HER2-positive early BC and residual disease after preoperative therapy
Track 2:
Side effects and quality of life associated with T-DM1 treatment
Track 3:
Case: A 57-year-old postmenopausal woman with an ER/PR-positive, HER2-positive infiltrating ductal carcinoma (IDC) and positive axillary lymph nodes achieves a clinical response to neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP)
Track 4:
Therapeutic options for patients with ER-positive, HER2-positive BC in the (neo)adjuvant setting
Track 5:
Efficacy of CDK4/6 inhibitors for patients with ER-positive, HER2-negative mBC
Track 6:
Benefits and risks with the addition of CDK4/6 inhibitors to hormone therapy
Track 7:
Perspective on the use of CDK4/6 inhibitors for elderly patients
Track 8:
Activity and tolerability of palbociclib, abemaciclib and ribociclib
Track 9:
Dosing considerations and adherence to treatment with CDK4/6 inhibitors
Track 10:
Activity of CDK4/6 inhibitors in patients with brain metastases
Track 11:
Ongoing Phase II PACE study evaluating the addition of palbociclib with or without avelumab to fulvestrant for patients who experience disease progression on a CDK4/6 inhibitor and endocrine therapy
Track 12:
Selection and sequencing of CDK4/6 inhibitors for patients with ER-positive, HER2-negative mBC
Track 13:
Case: A 58-year-old postmenopausal woman with a Grade III, ER/PR-positive, HER2-negative IDC and a RS of 12
Track 14:
Use of the 21-gene RS assay for patients with node-positive BC
Track 15:
Choice of endocrine therapy for premenopausal women with node-positive BC
Track 16:
Role of chemotherapy for patients with ER-positive, node-positive BC and an intermediate RS
Track 17:
Perspective on using genomic assays for ER-positive, HER2-negative, node-negative BC in the neoadjuvant setting
Track 18:
IMpassion130: A Phase III trial of atezolizumab with nab paclitaxel as first-line treatment for advanced TNBC
Track 19:
Case: A 55-year-old woman with ER/PR-positive, HER2-negative mBC and a germline BRCA2 mutation receives olaparib after disease progression on several lines of therapy
Track 20:
Efficacy of the PARP inhibitors talazoparib and olaparib in patients with BC and a germline BRCA mutation
Track 21:
Prognosis and outcomes for patients with pregnancy-associated BC
Track 22:
Case: A 32-year-old woman who is 12 weeks pregnant presents with a palpable breast mass and is diagnosed with ER-positive, HER2-positive BC
FACULTY
Joyce O’Shaughnessy, MD
Chair Breast Cancer Research Program
Baylor Charles A Sammons Cancer Center
Celebrating Women Chair in Breast Cancer Research
Texas Oncology
US Oncology
Dallas, Texas
Erica L Mayer, MD, MPH
Senior Physician
Susan F Smith Center for Women’s Cancers
Dana-Farber Cancer Institute
Assistant Professor in Medicine
Harvard Medical School
Boston, Massachusetts
EDITOR
Neil Love, MD
Research To Practice
Miami, Florida